8-K: Denali Therapeutics Announces Third Quarter 2024 Financial Results and Pipeline Progress

Denali Therapeutics reported its third quarter 2024 financial results, highlighted by progress in its Transport Vehicle (TV) enabled portfolio and plans for accelerated approval of tividenofusp alfa.

Summary

• Denali Therapeutics announced its financial results for the third quarter ended September 30, 2024, reporting a net loss of $107.2 million compared to a net loss of $99.4 million for the same period in 2023.
• The company's collaboration revenue decreased to $0 for the quarter, down from $1.3 million in the prior year, primarily due to changes in the Biogen Collaboration Agreement.
• Research and development expenses increased to $98.2 million, up from $89.7 million in the same quarter of 2023, driven by advancements in clinical programs and investments in the TV platform.
• Denali's cash, cash equivalents, and marketable securities totaled approximately $1.28 billion as of September 30, 2024.
• The company updated its full-year 2024 cash operating expense guidance, now anticipating a 5-10% increase compared to 2023, up from previous guidance of equal to or less than 2023 expenses.
• Denali is on track to file for accelerated approval of tividenofusp alfa in MPS II in early 2025 after a successful meeting with the FDA.
• Preliminary data from the Phase 1/2 study of DNL126 in MPS IIIA showed a robust reduction in CSF heparan sulfate levels, including normalization, leading to an expansion of the study to support a potential accelerated path.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive clinical progress but increased losses and expenses. The discontinuation of a partnered study is a negative, but the potential for accelerated approval of tividenofusp alfa is a positive. The sentiment is neutral to slightly negative.

Positives

• The FDA has agreed that cerebrospinal fluid heparan sulfate (CSF HS) can be used as a surrogate endpoint to support accelerated approval for tividenofusp alfa in MPS II.
• The preliminary data for DNL126 in MPS IIIA is very promising, showing a significant reduction in CSF HS levels.
• Denali's OTV platform has demonstrated the ability to achieve broad biodistribution of antisense oligonucleotides in the central nervous system.
• The company has a strong cash position of $1.28 billion, providing financial stability for ongoing research and development.

Negatives

• Denali reported a net loss of $107.2 million for the third quarter of 2024, an increase from the $99.4 million loss in the same period of 2023.
• Collaboration revenue decreased to $0 for the quarter, down from $1.3 million in the prior year.
• The K2 Phase 2 study for oditrasertib (SAR443820/DNL788) in multiple sclerosis was discontinued due to not meeting primary and key secondary endpoints.
• Operating expenses are expected to increase by 5-10% for the full year 2024, which is higher than previous guidance.

Risks

• The company faces risks related to the development and regulatory approval of its product candidates.
• There is a risk that clinical trial results may not align with preclinical or early clinical data.
• Denali is dependent on third parties for the manufacture and supply of its product candidates.
• The company's financial performance is subject to risks related to economic conditions and its ability to secure additional capital.
• There is a risk of potential adverse events, toxicities, or other undesirable side effects in clinical trials.

Future Outlook

Denali anticipates an increase of approximately 5-10% in cash operating expenses for the full year 2024 compared to 2023. The company plans to submit a BLA for tividenofusp alfa in early 2025 and continues to advance its TV platform portfolio.

Management Comments

• Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics, stated that they are making significant progress across their Transport Vehicle (TV)-enabled portfolio.
• Ryan Watts also mentioned that they are on track to file for accelerated approval of tividenofusp alfa in MPS II in early 2025 after a successful meeting with the FDA.

Industry Context

Denali's focus on developing therapeutics that cross the blood-brain barrier aligns with the growing industry interest in addressing neurodegenerative diseases. The company's progress in its TV platform and its various clinical programs positions it as a key player in this space. The discontinuation of the Sanofi partnered K2 study highlights the challenges in CNS drug development.

Comparison to Industry Standards

• Denali's approach to using surrogate endpoints like CSF HS for accelerated approval is consistent with strategies employed by other biotech companies developing therapies for rare diseases.
• The company's OTV platform and its ability to achieve broad biodistribution of oligonucleotides is a key differentiator compared to traditional drug delivery methods.
• The increase in R&D expenses reflects the high cost of clinical development, which is typical for companies in the biotech industry.
• The discontinuation of the K2 study is not uncommon in the pharmaceutical industry, where clinical trials often fail to meet endpoints. Companies like Biogen and Sanofi have also experienced similar setbacks in their CNS programs.
• Denali's cash position of $1.28 billion is relatively strong compared to other companies of similar size in the biotech sector, providing a buffer for ongoing operations and clinical trials.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and operating expenses.
• Employees may be impacted by the company's strategic decisions and program changes.
• Patients with neurodegenerative and lysosomal storage diseases may benefit from the company's ongoing research and development efforts.
• Collaborators like Sanofi and Biogen may be affected by the progress and setbacks of Denali's programs.

Next Steps

• Denali plans to submit a BLA for tividenofusp alfa in early 2025.
• The company will continue to advance its clinical programs, including DNL126, DNL343, and BIIB122.
• Denali will continue to develop its OTV and ATV platforms.
• The company will participate in several upcoming investor conferences.

Key Dates

Keywords

Denali Therapeutics, Transport Vehicle, Blood-Brain Barrier, Neurodegenerative Diseases, Lysosomal Storage Diseases, Tividenofusp alfa, MPS II, DNL126, MPS IIIA, Oligonucleotide Transport Vehicle, Accelerated Approval, Clinical Trials, Biotechnology